Skip to main content
Premium Trial:

Request an Annual Quote

VitaPath Genetics Lands $6M Equity Investment

NEW YORK (GenomeWeb News) – Molecular diagnostics developer VitaPath Genetics has raised $6 million in a private equity financing that was led by MDV-Mohr Davidow Ventures and included an investment from X/Seed Capital.

The company is developing a genetic test for spina bifida, a birth defect that affects the spine and which can be avoided with high doses of folic acid therapy.

The company plans to use the Series A financing to complete the validation of this first assay and to prepare for its commercial launch.

VitaPath Genetics CEO Bruce Cohen said in a statement that the firm's "unique approach to discovery and validation" will enable physicians to "identify and safely remediate mutations that would otherwise impair birth."

"Whereas most medicine is delivered after the fact, VitaPath provides actionable diagnostics to identify and prevent those most at risk from developing a disease or condition," MDV Partner Michael Goldberg added.

As part of the financing, Goldberg and X/Seed's Michael Borrus took seats on the firm's board of directors.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.